| Title |
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, October 2016
|
| DOI | 10.1007/s10549-016-4001-y |
| Pubmed ID | |
| Authors |
Sara M. Tolaney, Hovav Nechushtan, Ilan-Gil Ron, Patrick Schöffski, Ahmad Awada, Chris A. Yasenchak, A. Douglas Laird, Bridget O’Keeffe, Geoffrey I. Shapiro, Eric P. Winer |
| Abstract |
Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEGFR2, AXL, and other tyrosine kinases, was assessed in a cohort of metastatic breast cancer (MBC) patients in a phase II randomized discontinuation trial (RDT). Patients received 100 mg cabozantinib daily during a 12-week lead-in stage. Those with stable disease per modified Response Evaluation Criteria in Solid Tumors version 1.0 at 12 weeks were randomized to either continue cabozantinib or receive placebo. Primary endpoints were objective response rate (ORR) during the 12-week lead-in stage and progression-free survival (PFS) after randomization. Patients were also followed for overall survival (OS). Forty-five patients with MBC and a median of three prior lines of chemotherapy for metastatic disease were enrolled. The ORR during the lead-in stage was 13.6 % (95 % confidence interval [CI] 6-25.7 %), and the disease control rate at week 12 was 46.7 % (95 % CI 31.7-61.6 %). Per the initial RDT study design, patients with stable disease at week 12 were randomized to cabozantinib or placebo. Following a Study Oversight Committee recommendation, randomization was suspended. Patients in the lead-in stage continued on open-label cabozantinib. Patients in the randomization stage were subsequently unblinded. The overall median PFS for all MBC patients was 4.3 months. Median OS was 11.4 months (95 % CI 10.5-16.5 months). The most common grade 3/4 adverse events in the lead-in stage were palmar-plantar erythrodysesthesia (13 %) and fatigue (11 %). One death from respiratory failure was reported as drug-related during the lead-in stage. In heavily pretreated MBC patients, cabozantinib monotherapy demonstrated clinical activity including objective response and disease control. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 75 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 15% |
| Student > Ph. D. Student | 8 | 11% |
| Student > Master | 8 | 11% |
| Student > Bachelor | 8 | 11% |
| Other | 4 | 5% |
| Other | 15 | 20% |
| Unknown | 21 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 25% |
| Biochemistry, Genetics and Molecular Biology | 7 | 9% |
| Nursing and Health Professions | 6 | 8% |
| Agricultural and Biological Sciences | 4 | 5% |
| Sports and Recreations | 2 | 3% |
| Other | 6 | 8% |
| Unknown | 31 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2016.
All research outputs
#18,475,157
of 22,893,031 outputs
Outputs from Breast Cancer Research and Treatment
#3,721
of 4,661 outputs
Outputs of similar age
#242,066
of 319,910 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#54
of 78 outputs
Altmetric has tracked 22,893,031 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,661 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,910 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.